Cadonilimab plus anlotinib then radiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination therapy for people with recurrent or metastatic esophageal squamous cell carcinoma. First, you receive immunotherapy (cadonilimab) and a targeted drug (anlotinib), followed by radiation. The goal is to see if this approach helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent or metastatic esophageal squamous cell carcinoma confirmed by biopsy or cytology.
- You are at least 18 years old.
- Your overall health status is fairly good (ECOG score 0-2).
- You have not had prior systemic treatment for recurrent/metastatic disease, or you've had treatment that stopped working.
- You have at least one tumor that can be measured on a scan.
- You have adequate kidney, liver, and bone marrow function (based on blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (anlotinib), immunotherapy (toripalimab), and chemotherapy given before surgery for esophageal cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests an immunotherapy drug (adebrelimab) combined with chemotherapy before standard chemoradiation for people with locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
This study tests a combination of two drugs—cadonilimab (an immunotherapy) and anlotinib (a targeted therapy)—given before surgery for advanced esophageal cancer that can still be removed. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.